ANDOVER, Mass. & HAIFA, Israel--()--MeMed, a leader in host-response diagnostics, today announced the publication of three new peer-reviewed studies, reinforcing the real-world clinical and economic impact of MeMed BV, its flagship diagnostic for differentiating between bacterial and viral infections. Conducted across multiple centers in the U.S., Europe, and the U.K., and involving thousands of patients, these independent studies highlight distinct aspects of MeMed BV’s impact, including better antibiotic stewardship, superior performance over the standard of care, and reduced healthcare costs.

“What’s particularly remarkable is the sheer volume and caliber of new evidence emerging all at once, including real-world evidence,” said Eran Eden, Ph.D., Co-Founder and CEO of MeMed. “This reflects our deep commitment to advancing infectious disease diagnostics and pushing the boundaries of what’s possible.”

Study 1: MeMed BV Optimizes Antibiotic Use & Reduces Hospitalizations in Multi-Center Real-World Study. Published in BMC Medicine (Kalmovich et al.), this large-scale, real-world study evaluated 3,920 patients across 10 urgent care centers, involving 144 physicians using MeMed BV in routine practice. Key findings:

  • 63% reduction in unnecessary antibiotic prescriptions.
  • 70% of previously potentially missed bacterial infections correctly identified and treated, leading to significantly lower hospitalization rates (7.8% vs. 30.3%).
  • Helped in preventing emergency department (ED) referrals in 20% of patients.
  • Superior performance compared to traditional biomarkers, such as CRP and white blood cell count.

“Our real-world study highlights how MeMed BV impacts patient care in so many ways - from improving antibiotic stewardship to correctly identifying bacterial infections and preventing unnecessary ED referrals,” said Boaz Kalmovich, M.D., Head of the Urgent Care and Outpatient Clinics Division, Maccabi Healthcare Services, and lead author of this study.

Study 2: MeMed BV Outperforms Standard of Care, Including in Difficult-to-Diagnose Cases. Published in Clinical Infectious Diseases (Allen C et al.), this study examined 1,016 patients across 17 centers in the U.S. and EMEA, with a focus on:

  • MeMed BV’s high diagnostic accuracy, even in patients with ambiguous clinical presentations that are often overlooked.
  • Superior performance compared to the standard of care, particularly procalcitonin (PCT), in distinguishing between bacterial and viral infections.

Study 3: MeMed BV Demonstrates Cost Savings in Health Economics Study. Published in JAC-AMR (Gregg E et al.), this study assessed MeMed BV’s economic impact within the UK’s National Health Service (NHS), revealing:

  • Significant cost savings in testing for community-acquired pneumonia across both adult and pediatric populations, reinforcing its value in optimizing healthcare expenditures.

“Now that MeMed BV has been validated for accuracy, we are shifting the focus to its real-world impact—how it transforms patient care, supports clinical decisions, and improves healthcare efficiency at scale,” said Tanya Gottlieb, Ph.D., Vice President of Scientific Affairs at MeMed.

About MeMed

At MeMed, our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society.

MeMed BV® is the first FDA-cleared host-immune response test for accurately distinguishing between bacterial and viral infections in 15 minutes.

MeMed Severity™ has received FDA Breakthrough Device Designation as a host-response test designed to predict severe outcomes up to 72 hours and mortality 14 days in advance in patients with acute infections and suspected sepsis. MeMed Severity is not yet cleared for sale in any territory.

Follow and connect with MeMed via LinkedIn, X, and Facebook.